alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Disease mechanisms in lab and animal studies

1,352 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures

    ✓ Peer-reviewed alzhub usefulness score 84 out of 100. Brain : a journal of neurology 2026-01-08 Drug development

    Targeting of tau pathology has long been proposed as a potential therapeutic strategy for Alzheimer's disease (AD).

  2. A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Movement Disorders 2014-02-14 Clinical safety

    It is believed that glycogen synthase kinase-3 (GSK-3) hyperphosphorylates tau protein in progressive supranuclear palsy (PSP).

  3. Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-03 Disease mechanisms

    In Alzheimer's disease (AD), tau undergoes abnormal post-translational modifications and aggregations.

  4. Efficacy of Curcumin in Neurodegenerative Diseases: From Pharmacokinetic Barriers to Advanced Delivery Systems

    ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Pharmaceuticals (Basel, Switzerland) 2026-08-14 Clinical trials

    Curcumin exhibits neuroprotective activity in preclinical models of the four NDs analysed, acting on six interconnected mechanisms and the gut-brain axis.

  5. Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. JAMA neurology 2024-01-01 Biomarkers

    Overall the study included 199 participants with iRBD, 20 hyposmic participants with available dopamine transporter single-photon emission computed tomography, 146 nonmanifest GBA1N409S gene carriers, 21 GBA1N409S gene carrier patients with PD, 50 patients with sporadic PD, and 140 healthy controls.

  6. Functional screening in Drosophila identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Human Molecular Genetics 2013-09-25 Genetics

    Using a Drosophila model of Alzheimer's disease (AD), we systematically evaluated 67 candidate genes based on AD-associated genomic loci (P < 10(-4)) from published human genome-wide association studies (GWAS).

  7. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. The Journal of pharmacology and experimental therapeutics 2014-10-15 Drug development

    Methylthioninium (MT) is a tau aggregation inhibitor with therapeutic potential in Alzheimer's disease (AD).

  8. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Ageing research reviews 2021-10-21 Treatments

    Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing, affecting around 46 million people worldwide but few treatments are currently available.

  9. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Brain : a journal of neurology 2010-03-31 Treatments

    Hippocampal sections from five patients with Alzheimer's disease enrolled in the AN1792 Phase 2a trial were compared with those from 13 non-immunized Braak-stage and age-matched patients with Alzheimer's disease, and eight age-matched non-demented controls.

  10. Atrophy signature for alpha-synuclein copathology in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-05-24 Brain tissue and pathology

    Compared to CTR, both AD-αSAA- and AD-αSAA+ showed widespread cortical thinning.

  11. Synaptic Compensatory Plasticity in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2023-10-11 Disease mechanisms

    The loss of excitatory synapses is known to underlie the cognitive deficits in Alzheimer's disease (AD).

  12. Alzheimer's disease due to loss of function: A new synthesis of the available data

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Progress in neurobiology 2016-06-18 Biomarkers

    Alzheimer's Disease (AD) is a highly complex disease involving a broad range of clinical, cellular, and biochemical manifestations that are currently not understood in combination.

  13. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2015-01-01 Treatments

    BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD).

  14. Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Nature communications 2020-05-26 Brain scans and imaging

    Tau is a hallmark pathology of Alzheimer's disease, and animal models have suggested that tau spreads from cell to cell through neuronal connections, facilitated by β-amyloid (Aβ).

  15. TDP-43 pathology is associated with increased tau burdens and seeding

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Molecular neurodegeneration 2023-09-30 Brain tissue and pathology

    We found that AD cases with comorbid LATE-NC, AD(LATE-NC+), have increased burdens of pretangles and/or NFTs as well as increased brain levels of p-tau199, compared to AD(LATE-NC-) cases and controls.

  16. Novel tau filament fold in corticobasal degeneration

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Nature 2020-02-12 Genetics

    Corticobasal degeneration (CBD) is a neurodegenerative tauopathy-a class of disorders in which the tau protein forms insoluble inclusions in the brain-that is characterized by motor and cognitive disturbances 1-3 .

  17. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2007-10-01 Brain scans and imaging

    We provide the first evidence for the capability of a high-resolution positron emission tomographic (PET) imaging system in quantitatively mapping amyloid accumulation in living amyloid precursor protein transgenic (Tg) mice.

  18. Curcumin labels amyloid pathology in vivo , disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of Neurochemistry 2007-03-29 Vascular contributions

    Alzheimer's disease (AD) is characterized by senile plaques and neurodegeneration although the neurotoxic mechanisms have not been completely elucidated.

  19. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Nature medicine 2024-01-26 Biomarkers

    Although loss of TAR DNA-binding protein 43 kDa (TDP-43) splicing repression is well documented in postmortem tissues of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), whether this abnormality occurs during early-stage disease remains unresolved.

  20. Serum biomarkers associated with aging and neurodegeneration in common marmosets (Callithrix jacchus)

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neuroscience letters 2023-11-23 Biomarkers

    The common marmoset (Callithrix jacchus), a small South American monkey, is an important nonhuman primate model in the study of aging and age-related neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, and related dementias.

  21. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Brain : a journal of neurology 2015-12-08 Tau biomarkers

    Extracellular α-synuclein has been proposed as a crucial mechanism for induction of pathological aggregate formation in previously healthy cells.

  22. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Annals of neurology 2008-03-01 Brain scans and imaging

    The E693Delta mutation has been suggested as a cause of dementia because of enhanced formation of synaptotoxic Abeta oligomers.

  23. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Acta neuropathologica 2006-09-26 Brain scans and imaging

    We have investigated the extent and pattern of immunostaining for ubiquitin protein (UBQ) in 60 patients with frontotemporal lobar degeneration (FTLD) with ubiquitin-positive, tau-negative inclusions (FTLD-U), 37 of whom were ascertained in Manchester UK and 23 in Newcastle-Upon-Tyne, UK.

  24. AETA peptide contributes to Alzheimer's disease signature of synapse dysfunction

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Acta neuropathologica 2026-06-03 Disease mechanisms

    Alzheimer's disease (AD), the leading cause of dementia, is characterized by early synaptic dysfunction that precedes overt cognitive decline.

  25. α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. NPJ Parkinson's disease 2023-08-28 Brain tissue and pathology

    There is increasing interest in studying retinal biomarkers for various neurodegenerative diseases.

Other topics